[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:primary-effusion-lymphoma:kshv":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Primary Effusion Lymphoma","KSHV",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05907759","Daratumumab for Relapsed\u002FRefractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease",[12],"Phase 2","RECRUITING","2026-08-26T02:18:43.501109Z","2026-05-05T02:43:26.949844Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04968288","Natural History of KSHV-Associated Multicentric Castleman s Disease",[],"2026-08-26T02:19:07.104270Z","2026-05-13T02:55:06.275783Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT00006518","Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer",[],"2026-08-26T02:17:21.315591Z","2026-05-13T02:55:06.028653Z"]